The H3R antagonist/inverse agonist pitolisant (formerly known as BF2.649; tiprolisant) has been approved in the EU for the treatment of narcolepsy with or without cataplexy in adult patients and in the USA for the treatment of excessive daytime sleepiness in adult patients with narcolepsy [68]. This evidence concerns the gene HRH3 and narcolepsy.